We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns MJM for Misbranding After Repeated Violation Observations
FDA Warns MJM for Misbranding After Repeated Violation Observations
September 6, 2005
Non-response to a patient death as well as the repeated violation of previously cited agency observations were among the chief concerns highlighted by the FDA in a recent warning letter to MJM International.